An open-label, multi-centre, post-marketing study to assess the efficacy and safety of a plasma-derived VWF/FVIII concentrate in patients with von Willebrand disease.

More search options...

Miesbach, W; Halimeh, S; Platokouki, H; Podolak-Dawidziak, M; Zdziarska, J; Korczowski, B; Chowdary, P; Austin, S; Millar, C; Alamelu, J; et al. Miesbach, W; Halimeh, S; Platokouki, H; Podolak-Dawidziak, M; Zdziarska, J; Korczowski, B; Chowdary, P; Austin, S; Millar, C; Alamelu, J; Rogosch, T; Pabinger, I (2024) An open-label, multi-centre, post-marketing study to assess the efficacy and safety of a plasma-derived VWF/FVIII concentrate in patients with von Willebrand disease. Haemophilia, 30 (1). pp. 236-240. ISSN 1365-2516 https://doi.org/10.1111/hae.14868
SGUL Authors: Austin, Steve

Preview

PDF Published Version
Available under License Creative Commons Attribution Non-commercial.
Download (192kB) | Preview

Official URL: https://doi.org/10.1111/hae.14868

Item Type:

Article

Additional Information:

© 2023 The Authors. Haemophilia published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Keywords:

Humans, von Willebrand Diseases, von Willebrand Factor, Factor VIII, Patients, 1103 Clinical Sciences, Cardiovascular System & Hematology

SGUL Research Institute / Research Centre:

Academic Structure > Institute of Medical, Biomedical and Allied Health Education (IMBE)

Journal or Publication Title:

Haemophilia

ISSN:

1365-2516

Language:

eng

Publisher License:

Creative Commons: Attribution-Noncommercial 4.0